
Description
Ozempic and Mounjaro have transformed the conversation around weight loss, but the science behind these medications extends well beyond the scales. Originally developed to help manage type 2 diabetes, GLP-1 medications are now being used to treat obesity, while researchers investigate their potential benefits for cardiovascular health, kidney disease and other chronic conditions. But how much do we really know about their long term safety? What happens when people stop taking them? And are their growing popularity and use for weight loss running ahead of the science? Professor Stephen Hall, Adjunct Professor of Medicine at Monash University and an experienced clinical trials researcher, joins us to examine the promise, risks and unanswered questions surrounding the GLP-1 revolution.
This program is intended for general information and educational purposes only and does not constitute medical advice. The information discussed should not be used as a substitute for professional medical advice, diagnosis or treatment. Consult your qualified healthcare professional.
This program is intended for general information and educational purposes only and does not constitute medical advice. The information discussed should not be used as a substitute for professional medical advice, diagnosis or treatment. Consult your qualified healthcare professional.
Comments
No comments yet — be the first to write one.